論文

査読有り
2017年3月1日

Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1

Respiratory Investigation
  • Soji Kakiuchi
  • Masaki Hanibuchi
  • Toshifumi Tezuka
  • Atsuro Saijo
  • Kenji Otsuka
  • Satoshi Sakaguchi
  • Yuko Toyoda
  • Hisatsugu Goto
  • Hiroshi Kawano
  • Masahiko Azuma
  • Fumitaka Ogushi
  • Yasuhiko Nishioka
  • 全て表示

55
2
開始ページ
145
終了ページ
152
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.resinv.2016.10.008
出版者・発行元
Elsevier B.V.

Background Interstitial lung disease (ILD) is commonly concomitant with lung cancer, and its acute exacerbation (AE) is the most serious complication in patients receiving treatment for lung cancer. Methods To investigate the incidence and characteristic features of AE of ILD, we conducted a retrospective study of 665 consecutive patients with lung cancer who were treated at our institute between 2008 and 2014. Results Among the 665 patients, 74 (11.1%) had preexisting ILD, and 64 of them received chemotherapy. Four of the 64 patients (6.3%) had experienced AE of ILD, and two (3.1%) died of respiratory failure during first-line chemotherapy. The use of a combination of carboplatin with tegafur-gimeracil-oteracil potassium (S-1) or paclitaxel as a first-line chemotherapy for non-small cell lung cancer led to a lower frequency of AE, at 8.3% (1/12) and 9.1% (1/11), respectively. The incidence of AE rose to 12.8% (5/39) during second-line treatment, and 14 (total: 15 times) of the 64 patients (21.9%) experienced AE from the time of diagnosis to the end of treatment. The incidence of AE was 17.7% (6/34), 15.8% (3/19), 5.0% (2/40), and 4.2% (1/24) in the paclitaxel-, vinorelbine-, etoposide-, and S-1-containing regimens, respectively. No difference in clinical features and laboratory data was detected between the AE and non-AE groups. Conclusions Although this was a small retrospective study, its findings showed that S-1 and etoposide may be relatively safe options for the treatment of patients with lung cancer and concomitant ILD.

リンク情報
DOI
https://doi.org/10.1016/j.resinv.2016.10.008
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28274530
ID情報
  • DOI : 10.1016/j.resinv.2016.10.008
  • ISSN : 2212-5353
  • ISSN : 2212-5345
  • PubMed ID : 28274530
  • SCOPUS ID : 85008195179

エクスポート
BibTeX RIS